In the latter, Lyn up-regulation and activation are associated with expression of Bcl-2, which is often silenced in BCR-ABL-positive CML cells, which in turn confers imatinib resistance (100). This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.